Showing results (101-110 of 198) with videos related to
Sort By:
Pageof 20
European Urology Oncology|August 22, 2022
Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate CancerJustin R Gregg, Jeri Kim, Christopher Logothetis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium studyThehang H Luu, Robert J Morgan, Lucille Leong, et al.European Urology|July 10, 2012
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinomaNizar M Tannir, Elizabeth Plimack, Chaan Ng, et al.Nature Reviews. Urology|April 7, 2021
Optimizing the diagnosis and management of ductal prostate cancerWeranja Ranasinghe, Daniel D Shapiro, Miao Zhang, et al.Cancer|May 27, 2020
Patterns of metastases of prostatic ductal adenocarcinomaWeranja K B Ranasinghe, Nathan A Brooks, Mohamed A Elsheshtawi, et al.Radiology. Imaging Cancer|February 25, 2022
18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-AnalysisDivya Yadav, Hyunsoo Hwang, Wei Qiao, et al.Science Translational Medicine|May 10, 2023
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficienciesWei Shi, Yin Wang, Yuehui Zhao, et al.Biorxiv : the Preprint Server for Biology|May 18, 2026
Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisJavier Leo, Feiyu Chen, Wei Shi, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancerJeri Kim, Peiyu Sun, Ying-Wai Lam, et al.Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.Pageof 20